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Abstract 
 
Introduction 
Respiratory Syncytial Virus (RSV) is a common cause of infant hospitalisation 
and mortality. With multiple vaccines in development, we aimed to determine 
[1] the awareness of RSV amongst pregnant women and healthcare professionals 
(HCPs), and [2] attitudes towards clinical trials and routine implementation of 
antenatal RSV vaccination. 
 
Methods 
Separate questionnaires for pregnant women and HCPs were distributed within 
four hospitals in South England (July 2017-January 2018). 
 
Results 
Responses from 314 pregnant women and 204 HCPs (18% obstetricians, 75% 
midwives, 7% unknown) were analyzed.  Most pregnant women (88%) and 
midwives (66%) had no/very little awareness of RSV, unlike obstetricians 
(14%).  Amongst pregnant women, 29% and 75% would likely accept RSV 
vaccination as part of a trial, or if routinely-recommended, respectively. Younger 
women (16-24 years), those of 21-30 weeks’ gestation, and with experience of 
RSV were significantly more likely to participate in trials (OR: 1.42 [1.72-9.86]; 
OR: 2.29 [1.22-4.31]; OR: 9.07 [1.62-50.86], respectively). White-British women 
and those of 21-30 weeks’ gestation were more likely to accept routinely-
recommended vaccination (OR: 2.16 [1.07-4.13]; OR: 2.10 [1.07-4.13]). 
Obstetricians were more likely than midwives to support clinical trials (92% vs. 
68%, OR: 2.50, 1.01-6.16) and routine RSV vaccination (89% vs. 79%, OR: 4.08, 
1.53-9.81), as were those with prior knowledge of RSV, and who deemed it 
serious.  
 
Conclusion 
RSV awareness is low amongst pregnant women and midwives. Education will 
be required to support successful implementation of routine antenatal 
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vaccination. Research is needed to understand reasons for vaccine hesitancy 
amongst pregnant women and HCPs, particularly midwives. 
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Introduction 
 
Respiratory Syncytial Virus (RSV) is the leading viral cause of lower respiratory 
tract infection and bronchiolitis in infants, and is a major cause of hospitalization 
and mortality worldwide 1. RSV infects more that 60% of children in their first 
year of life, and almost 100% by two years of age 2. The estimated case fatality 
ratio for children hospitalized with severe RSV disease is 0.3% in industrialized 
countries, and 2.1% in developing countries3. Severe illness often occurs in 
children under six months 4, particularly in those born prematurely or with 
underlying chronic illness, and the development of novel prevention and 
treatment strategies is an international priority 5 6. 
 
Antenatal vaccination is an effective means of protecting young infants from 
infection when the period of greatest susceptibility is shortly after birth 7–10 , and 
is now routinely recommended for use against a number of pathogens, including 
tetanus, influenza and pertussis 11. No vaccine against RSV is yet approved for 
routine use, however a number of candidates are in development 12 13, one of 
which is undergoing international phase III efficacy trials in pregnant women 
(NCT02624947)  11 14. An advantage of vaccination in pregnancy, rather than 
infancy, is that protection is afforded to infants from birth and extends through 
the period of highest risk of severe disease.  
 
Achieving vaccine acceptance amongst pregnant women and maternity 
healthcare professionals (HCPs) has proven to be a considerable public health 
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challenge, particularly in developed countries, and uptake of routine vaccination 
(especially influenza) remains suboptimal 15 . Furthermore, recruitment of 
pregnant women into clinical trials may be difficult, particularly as historically 
they have been excluded from participation, and there is a paucity of information 
regarding their recruitment and retention16 17. Pre-emptively ascertaining the 
level of awareness of RSV amongst pregnant women and HCPs, as well as their 
attitudes to vaccine clinical trials and routine implementation of an RSV vaccine, 
may allow us to identify interventions to optimise both recruitment for future 
trials and uptake in a routine setting. 
 
Our aims were to determine [1] the level of awareness of RSV amongst pregnant 
women and HCPs, and [2] their attitudes towards clinical trials and routine 
implementation of RSV antenatal vaccination.  
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Methods 
 
Questionnaire design and development 
Two separate anonymized questionnaires were developed for pregnant women 
and maternity HCPs (see supplementary information). These were developed 
with input from a multi-disciplinary study team including pediatricians, 
obstetricians, and health psychologists. Pregnant women and maternity HCPs 
were asked about their awareness and experience of RSV and bronchiolitis, 
pregnant women were asked whether they would hypothetically consider 
receiving an RSV vaccine as part of a clinical trial or if a vaccine were routinely 
recommended, and maternity HCPs if they would support clinical trials and 
routine recommendations. Women were also asked about the number of 
vaccines they would deem acceptable during pregnancy, and their opinions 
regarding the design of vaccine clinical trials. Part way through the 
questionnaire (having completed a self-assessment of their prior 
awareness/experience of RSV and bronchiolitis), participants were provided 
with written information on RSV and bronchiolitis inside a sealed envelope. This 
was done in order to inform further questions, whilst avoiding biasing their self-
assessment in the previous section. Ethical approval was granted (reference 
17/LO/0537) and the study was registered on ClinicalTrials.gov prior to 
recruitment (NCT03096574). 
 
Study population and recruitment 
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The questionnaire for pregnant women was administered to women (aged > 16 
years at the time of recruitment) attending for routine antenatal care at four 
study sites in southern England: University Hospital Southampton NHS 
Foundation Trust, Oxford University Hospitals NHS Foundation Trust, University 
Hospitals Bristol NHS Foundation Trust, and St George’s University Hospitals 
NHS Foundation Trust, London. These four study sites were selected due to their 
high birth rates (all >4000 births/year 18), and by distributing our questionnaire 
across four hospitals we attempted to increase the demographic diversity of our 
study population. The HCP questionnaire was administered to those working in 
either midwifery or obstetrics at the same four sites. Antenatal care for low-risk 
women in the UK is midwife-led, with women only seeing an obstetrician if they 
have a high-risk pregnancy, therefore the majority of potential respondents to 
our questionnaire were midwives.  
 
Recruitment of participants took place from July 2017 to January 2018. Pregnant 
women were recruited in-person at antenatal clinics and wards by members of 
the study team on an opportunistic (non-sequential) basis over the recruitment 
period, and given paper questionnaires to complete. For recruitment of HCPs, all 
obstetricians and midwives at the participating institutions were identified by a 
senior member of staff not involved in the study (using email distribution lists). 
They were then contacted via an email containing a link to an online 
questionnaire, followed by two email reminders. Alternatively, HCPs may also 
have been recruited in-person by the study team (in a similar fashion to 
pregnant women), in which case they were also given paper questionnaires. At 
the time of recruitment, information provided on the nature of the questionnaire 
 9 
was kept to a minimum in order to avoid biasing participant responses. The 
participant information sheet stated only that the aim of the study was to better 
understand their attitudes towards RSV and vaccination during pregnancy. 
Participation in the study was voluntary and no financial or other incentive was 
offered. All participants gave informed consent. 
 
Questionnaire data analysis 
Questionnaire data were entered at the lead site (Southampton) into iSurvey 
(www.isurvey.soton.ac.uk). Statistical analysis was performed using IBM SPSS 
Statistics version 25. Ordinal regression analysis was performed, and adjusted 
odds ratios (ORs) and 95% confidence intervals (CI) were calculated. P-values 
<0.05 were considered as statistically significant. Multicollinearity was examined 
using the tolerance test and the Variance Inflation Factor (VIF) to ensure 
variables with a VIF value exceeding 2.5 were not entered into the multivariate 
regression analysis. 
 
 
 
 10 
Results 
 
A total of 525 participants completed the questionnaires: 321 pregnant women 
and 204 HCPs (18% obstetricians, 75% midwives, and for 7% the professional 
role was unknown). Seven questionnaires from pregnant women, and five from 
HCPs, were excluded due to largely incomplete or illegible responses, leaving 
513 (98%) for analysis. The numbers of respondents were equally distributed 
between the four study sites. The full characteristics of respondents are 
displayed in Table 1.  
 
Responses from pregnant women  
Most pregnant women reported no (71%) or very little (17%) awareness of RSV, 
and reported no experience (93%) [see Figure 1]. They were much more familiar 
with the term ‘bronchiolitis’ (only 14% had never heard of it), and bronchiolitis 
tended to be perceived as more common and serious than RSV.  
 
Of 312 who responded, 28% were likely/very likely, 32% not sure, and 40% 
unlikely/very unlikely to consider receiving RSV vaccination as part of a clinical 
trial. The most important information to women was the likelihood of side 
effects for their baby (see Figure 2). Ordinal regression analysis (see Table 2) 
demonstrated that women were significantly more likely to accept RSV 
vaccination as part of a clinical trial if they had direct experience of RSV (OR: 
9.07, 95% CI: 1.62-50.86), were of younger age (16-24 years, OR: 1.42, 95% CI: 
1.72-9.86) and of 21-30 weeks’ gestation (OR: 2.29, 95% CI: 1.22-4.31). Women 
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were significantly less likely to consider taking part if they perceived 
bronchiolitis as extremely/moderately serious (OR: 0.38, 95% CI: 0.15-0.93) or 
somewhat serious (OR: 0.27, 95% CI: 0.11-0.68).  
 
More women would accept the vaccine if it was routinely recommended: of 308 
who responded, 40% were very likely, 35% likely, 16% not sure, 5% unlikely 
and 4% very unlikely. Women were significantly more likely to accept routine 
RSV vaccination if they identified as White British (OR: 2.16, 95% CI: 1.22-3.83) 
versus non-White British, and were of 21-30 weeks’ gestation (OR: 2.10, 95% CI: 
1.07-4.13) 
 
The most popular method of being approached regarding study involvement was 
face-to-face by their midwife (37%), but 26% wouldn’t have a preference (see 
Figure 3). The amount of time pregnant women would need to consider whether 
or not to participate in a trial was variable, but 72% responded < one week (17% 
<24 hours, 22% 1-2 days, 33% 3-7 days, 18% 2-3 weeks, and 10% >1 month). 
For the majority (82%), their decision to participate wouldn’t be altered if the 
study was a randomised controlled trial, but 15% would be less likely to take 
part, and 3% would be more likely. For 66%, their decision wouldn’t be altered if 
the study involved different doses of vaccine, but 31% would be less likely to 
take part, and 3% would be more likely. The number of vaccines in pregnancy 
deemed acceptable by women was variable, however 25% would accept two 
vaccines or less, 27% would accept three, 11% four, 6% five, and 32% would 
accept more than five (i.e. as many as were recommended). Finally, in the free-
text comments (see supplementary information), some women raised concerns 
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regarding side-effects for their baby, and others stated support for vaccination, 
often describing personal experience.  
 
Responses from maternity healthcare professionals 
HCPs had greater awareness and experience of RSV than pregnant women, 
however obstetricians were significantly more familiar than midwives with both 
RSV (OR: 9.42, 95% CI: 5.08-25.30, p<0.0001) and bronchiolitis (OR 2.68, 95% 
CI: 1.29-5.55, p=0.008) [see Figure 1]. 
 
Of 192 HCPs who responded, 72% were likely/very likely, 19% not sure, and 9% 
unlikely/very unlikely to support a clinical trial of RSV vaccination. The most 
important information to HCPs was the likelihood of side effects for the baby.  
Ordinal regression analysis (see Table 2) demonstrated that HCPs were 
significantly more likely to consider supporting a clinical trial if they were 
obstetricians (OR: 2.50, 95% CI: 1.01-6.16), had good/some understanding of 
RSV (OR: 4.42, 95% CI: 1.10-17.83), and perceived RSV as extremely (OR: 4.85, 
95% CI: 1.11-21.28) or moderately/somewhat serious (OR: 4.16, 95% CI :1.26-
13.75). Likelihood of support also varied between study sites, with HCPs from 
sites A, B and C being significantly more likely to support a trial than those in site 
D.  
 
More HCPs would support administration of the vaccine if it was routinely 
recommended: 47% definitely, 34% likely, 14% not sure, 4% unlikely and 0.5% 
very unlikely. Obstetricians were significantly more likely than midwives to 
support the administration of a routine RSV vaccine (OR: 4.08, 95% CI: 1.53-
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9.81), as were those HCPs with good/some understanding of RSV (OR: 6.07, 95% 
CI: 1.23-29.93) and those who perceived RSV as moderately/somewhat serious 
(OR: 4.41, 95% CI: 1.32-14.78) [see Table 3]. Likelihood of supporting a routine 
RSV vaccine also varied significantly by study site with HCPs from sites A, B 
being significantly more likely to support routine vaccination than those in site 
D. Finally, in the free-text comments [see supplementary information] some 
HCPs reported concerns regarding the possibility of side-effects for the baby. 
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Discussion 
 
The high burden of RSV infection has driven recent efforts to develop an effective 
antenatal vaccine. This is a large multi-centre study in which we have attempted 
to establish the level of awareness of RSV, and attitudes to vaccine clinical trials 
and routine implementation of an RSV vaccine during pregnancy.  
 
The awareness of RSV was low amongst pregnant women and midwives, 
compared with obstetricians. Younger pregnant women, those of 21-30 weeks’ 
gestation, and those recalling direct experience of RSV, were significantly more 
likely to consider involvement in an RSV vaccine trial; and direct face-to-face 
interaction with a midwife was the preferred method of potential recruitment 
(amongst those who had a preference). Encouragingly, the majority of women 
would accept routine RSV vaccination, yet some (25%) would still be unsure or 
unlikely to accept vaccination, particularly those of ethnic minorities, and one-
quarter would accept < 2 vaccines during pregnancy. Approximately 70% and 
80% of HCPs would be likely to support an RSV vaccine trial and routine RSV 
vaccination respectively. Obstetricians were more likely than midwives to 
support both RSV trials and routine vaccination, as were those with prior 
knowledge of RSV and those who perceived it as a serious cause of infection. 
Support for potential RSV trials and routine vaccination also varied significantly 
by study site.  
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It is notable that the awareness of RSV is so low given that RSV-associated 
respiratory tract infection is one of the commonest causes of infant 
hospitalisation and mortality worldwide 1. Being thoroughly informed as to the 
indication and efficacy of vaccination has been shown to significantly increase 
the probability of its acceptance19 20. Therefore, with a number of RSV vaccine 
candidates currently in development, further education of both pregnant women 
and HCPs will be needed if we are to optimise engagement with vaccination 
trials and eventual uptake of RSV vaccines as part of routine care. Both pregnant 
women and HCPs seemed to better identify with the term bronchiolitis than RSV, 
and therefore specifically highlighting the link between these may be helpful in 
educational strategies. We do note that those who perceived bronchiolitis as 
serious were significantly less likely to consider participating in an RSV trial, 
however it is possible that this is a result of confounding due to a lack of 
knowledge regarding bronchiolitis. It is also interesting to note that women of 
21-30 weeks’ gestation were significantly more accepting of both RSV trials and 
routine vaccination, perhaps due to a sense of reassurance following their 20-
week anomaly scan and subsequent clinical review. Finally, the finding that 
women of ethnic minorities were less likely to accept routine RSV vaccination 
has been similarly observed in a number of previous studies of routinely-
recommended vaccines21–23, yet the underlying reasons remain poorly 
understood, and may include cultural/religious differences, as well as language 
barriers. 
 
It is concerning that a number of the HCPs surveyed in this study would be 
unlikely to support either clinical trials or routine vaccination against RSV. 
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Maternity HCPs can be strong advocates for antenatal vaccination, and 
encouragement from them (particularly midwives) may increase intention by up 
to 20 times2425. Furthermore, HCPs are well-placed to facilitate clinical trial 
recruitment by identifying and speaking directly to eligible women, and 
addressing specific concerns about research safety and practicality17. It is 
important to note that obstetricians were significantly more willing to provide 
support for both clinical trials and routine vaccination than midwives, 
independent of their prior knowledge/experience of RSV or bronchiolitis. 
Barriers to engagement of midwives and nurses in research that have been 
identified in previous studies, include high workload, insufficient staff numbers 
and resources, a lack of confidence, and a lack of a research-supportive culture 26 
27. Finally, the observed differences in support for both routine vaccination and 
clinical trials between study sites also suggests that there may be a potential risk 
of health inequalities based on differing recommendations across the South of 
England. All four sites had been involved in trials of antenatal vaccination 
(including RSV trials) prior to this study, and all have recently embedded 
vaccination into their routine antenatal care service. Site D only recently set up 
this vaccination service however (following the completion of this study), 
whereas it has been operating at the other sites for a longer period of time. They 
also report having comparatively less involvement from clinical teams in their 
vaccination trials. This may therefore, at least in part, explain the lower 
acceptance at this institution compared with sites A, B and C. 
 
Implications for clinical practice and research 
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It is clear that education about RSV and bronchiolitis for pregnant women will be 
required in order to optimise uptake rates of antenatal RSV vaccination if it is 
introduced into routine care. Such education should highlight the safety and 
benefits of vaccination for their child, as studies have consistently shown that 
perception of potential harm to the baby is the primary reason for vaccine 
refusal 25 28, whereas messages emphasising the protective benefits conferred to 
infants is a major motivator for pregnant women to undergo vaccination 29. As 
well as face-to-face counselling, possible strategies could include paper and 
online education resources 40  30, as well as mobile phone text messages (such as 
Text4baby 31) and smart phone apps (such as MatImms 32). Education for HCPs 
on RSV and bronchiolitis will also be required in order to ensure active 
promotion of vaccination, and individual institutions should aim to tackle any 
general vaccine hesitancy within their own working body. 
 
With regards to improving uptake into future antenatal vaccine trials, it is 
important to note that the majority of our respondents wouldn’t be deterred by a 
randomized controlled trial design, and that direct face-to-face interaction with 
an HCP was the preferred method of recruitment. Improving study team 
outreach and forming integrated networks between research teams and 
healthcare providers/clinical staff may help improve clinicians’ willingness to 
promote clinical studies to their patients, as well as pregnant women's 
willingness to join studies 17, and this has proven a successful method of 
recruiting pregnant women in previous studies 33 34. Social media and web-based 
recruitment may be used as a cost-effective supplement to traditional 
recruitment methods, and facilitate participation of traditionally harder-to-reach 
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populations 17 35, however this approach may be less successful for higher-risk 
intervention-based studies, including antenatal vaccine trials. 
 
Finally, it should be noted that there are other potential antenatal vaccines in 
development (including group B streptococcus and cytomegalovirus 11), for 
which education and support from staff will also be required for successful 
implementation 22 . Furthermore, it is also worth considering that whilst a third 
of our respondents would accept as many vaccines as were recommended, many 
women may be reluctant to accept high numbers of vaccines, especially if given 
on separate occasions36 37. Pragmatic research is therefore required to consider 
the logistical aspects of future antenatal vaccine delivery.  
 
Strengths and limitations  
This study had significant numbers of respondents, and by distributing our 
questionnaire across four hospitals in southern England we attempted to 
maximise the diversity of our study population. That said, the responses to the 
questionnaire cannot be taken as representative of all pregnant women and 
maternity HCPs. Our respondents were all recruited from antenatal clinics based 
in tertiary hospitals, and therefore it is also possible that our sample was missing 
subsets of the population that tend to be more anti-vaccination. Future studies 
might benefit from recruiting over a wider geographical area, and from different 
types of sites (such as non-tertiary hospitals and primary care), and perhaps 
utilising online recruitment via pregnancy-associated websites and social media. 
It may have been also beneficial to collect socio-economic data from our 
participants in order to assess the representativeness of our study sample. Other 
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limitations are that data on the uptake of antenatal vaccination was not collected 
from women’s medical records following delivery, and data on the uptake of 
influenza vaccination amongst HCPs wasn’t collected. Finally, the number of 
pregnant women/HCPs approached, and the number who declined participation 
(as well as their reasons for doing so) was not recorded, and we are therefore 
unable to report this data. 
 
Conclusions 
RSV awareness appears low amongst pregnant women and midwives in the UK. 
Education will be required to optimise engagement with vaccination trials and 
eventual uptake of RSV vaccination following routine implementation, with an 
emphasis on women of ethnic minorities. Active promotion of vaccination must 
be incorporated into routine antenatal care, and further research is needed to 
understand reasons for vaccine hesitancy amongst both pregnant women and 
HCPs, particularly midwives. 
 
 
 
 20 
Figure captions [images to be reproduced in colour online only]: 
 
Figure 1: Reported familiarity and experience with RSV (A & B) and 
bronchiolitis (C) amongst pregnant women, midwives and obstetricians, prior to 
their involvement in this study. 
 
Figure 2: Information that would be considered most important to the pregnant 
women in this study when deciding whether to take part in a research study of 
an RSV vaccine (A), and other factors which would discourage them from taking 
part (B). 
 
Figure 3: Preferred method of being approached regarding potential clinical trial 
involvement amongst the pregnant women in this study 
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Table 1: Characteristics of the questionnaire respondents (pregnant women and maternity 
healthcare professionals) 
 
 
 
Characteristic Pregnant women, 
n=314 
Healthcare professionals, 
n=199 
Age   
     16-24 34 (11%)  
     25-30 107 (34%)  
     31-35 92 (29%)  
     36-40 58 (19%)  
     41+ 13 (4%)  
Gestation (weeks)   
     <12 8 (2%)  
     12-16 37 (12%)  
     17-20 31 (10%)  
     21-30 55 (18%)  
     31-36 93 (30%)  
     >37 76 (24%)  
Study site   
     A 88 (28%) 43 (22%) 
     B 77 (25%) 53 (27%) 
     C 79 (25%) 61 (31%) 
     D 70 (22%) 42 (21%) 
Ethnicity   
     Asian (British, Indian, Pakistani, Bangladeshi, Chinese, 
other) 
25 (8%) 4 (2%) 
     Black (British, African, Caribbean, other) 17 (5%) 4 (2%) 
     White (British, Irish, other) 248 (79%) 175 (88%) 
     Mixed (Caribbean, African, Asian, other) 11 (4%) 6 (3%) 
     Other ethnic group (Arab, other) 3 (1%) 0 (0%) 
     Did not want to say 1 (0.3%) 1 (1%) 
     No response 10 (3%) 9 (5%) 
Has children   
    No 142 (45%) 72 (36%) 
    Yes 172 (55%) 127 (64%) 
Profession   
     Obstetrics  37 (19%) 
     Midwifery  151 (76%) 
     No response  11 (6%) 
Midwifery seniority   
     Band 5 (newly-qualified midwife)  8 (5%) 
     Band 6 (junior midwife)  84 (56%) 
     Band 7 (senior midwife)  46 (30%) 
     Band 8 (midwifery manager)  8 (5%) 
      No response  5 (3%) 
Obstetrician seniority   
     Specialty training years 1-3 (or equivalent)  8 (22%) 
     Specialty training years 4-6 (or equivalent)  6 (16%) 
     Specialty training years 7-8 (or equivalent)  6 (16%) 
     Consultant  17 (46%) 
Time spent working in maternity care (years)   
     <2  17 (9%) 
     2-5  29 (15%) 
     6-10  37 (19%) 
     11-15  20 (10%) 
     16-20  26 (13%) 
     >21  62 (31%) 
     No response  8 (4%) 
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Table 2: Ordinal regression analysis of factors predicting pregnant women’s willingness to 
consider undergoing RSV vaccination during pregnancy as part of a clinical trial, or if routinely 
recommended 
 
*=p<0.05; **=p<0.01 
Variable  
  
Number who’d be 
‘extremely likely’ or 
‘likely’ to accept RSV 
vaccination as part of 
a clinical trial 
Adjusted odds ratio 
(95% CI) 
Number who’d be 
extremely likely’ or 
‘likely’ to accept RSV 
vaccination if routinely 
recommended 
Adjusted odds 
ratio (95% CI) 
Age in years     
16-24 18/34 (53%) 1.42 (1.72-9.86) ** 27/34 (79%) 0.68 (0.28-1.67) 
25-35 54/199 (27%) 1.18 (0.67-2.07) 149/198 (75%) 0.71 (0.39-1.28) 
36-45 16/70 (23%) 1.00 for reference 53/70 (76%) 1.00 for reference 
Gestation in weeks     
<12 3/8 (38%) 1.99 (0.46-8.51) 6/8 (75%) 0.67 (0.15-3.00) 
12-20 24/68 (35%) 1.26 (0.72-2.22) 52/68 (76%) 1.17 (0.65-2.10) 
21-30 18/55 (33%) 2.29 (1.22-4.31) ** 42/54 (78%) 2.10 (1.07-4.13) * 
31+ 43/168 (26%) 1.00 for reference 128/168 (76%) 1.00 for reference 
Study site     
Site A 25/86 (29%) 0.80 (0.40-1.59) 65/87 (75%) 0.99 (0.49-2.00) 
Site B 23/77 (30%) 0.72 (0.35-1.49) 62/76 (82%) 1.26 (0.59-2.69) 
Site C 20/79 (25%) 0.54 (0.26-1.10) 55/76 (72%) 0.78 (0.37-1.63) 
Site D 20/70 (29%) 1.00 for reference 50/69 (72%) 1.00 for reference 
Previous children     
Yes 50/171 (29%) 1.13 (0.71-1.81) 122/171 (71%) 0.64 (0.39-1.05) 
No 39/141 (28%) 1.00 for reference 110/137 (80%) 1.00 for reference 
Ethnicity     
White British 66/224 (29%) 1.27 (0.73-2.21) 177/223 (79%) 2.16 (1.22-3.83) ** 
Non-White British 23/88 (26%) 1.00 for reference 55/85 (65%) 1.00 for reference 
Previous RSV experience     
Direct experience 5/8 (63%) 9.07 (1.62-50.86) * 8/8 (100%) 8.20 (0.71-94.16) 
Indirect experience 5/13 (38%) 1.11 (0.32-3.81) 10/13 (77%) 1.09 (0.30-3.96) 
No experience 79/291 (27%) 1.00 for reference 214/287 (75%) 1.00 for reference 
RSV familiarity     
Good/some understanding 5/14 (36%) 0.54 (0.12-2.30) 11/14 (79%) 1.77 (0.37-8.56) 
Poor understanding 21/77 (27%) 0.80 (0.47-1.38) 55/76 (72%) 0.96 (0.55-1.68) 
No understanding  63/219 (29%) 1.00 for reference 164/216 (76%) 1.00 for reference 
Perceived RSV frequency     
Extremely/moderately common 18/50 (36%) 1.12 (0.53-2.35) 39/51 (76%) 1.03 (0.47-2.23) 
Somewhat common 34/99 (34%) 1.52 (0.88-2.61) 75/98 (77%) 0.93 (0.53-1.64) 
Slightly/not at all common 37/143 (26%) 1.00 for reference 107/141 (76%) 1.00 for reference 
Perceived RSV severity     
Extremely/moderately serious 43/129 (33%) 1.22 (0.58-2.57) 100/129 (78%) 1.31 (0.60-2.86) 
Somewhat serious 33/117 (28%) 0.93 (0.47-1.84) 87/115 (76%) 1.06 (0.52-2.18) 
Slightly/not at all serious 13/43 (30%) 1.00 for reference 33/43 (77%) 1.00 for reference 
Bronchiolitis familiarity and experience     
Good/moderate understanding and 
direct/indirect experience  
27/88 (31%) 1.30 (0.65-2.60) 68/89 (76%) 0.75 (0.36-1.53) 
Slight understanding 29/102 (28%) 1.13 (0.63-2.00) 77/101 (76%) 0.81 (0.44-1.48) 
No understanding 32/120 (27%) 1.00 for reference 86/116 (74%) 1.00 for reference 
Perceived bronchiolitis frequency     
Extremely/moderately common 33/107 (31%) 0.67 (0.33-1.37) 85/107 (79%) 1.04 (0.49-2.19) 
Somewhat common 26/96 (27%) 1.25 (0.68-2.31) 69/95 (73%) 1.36 (0.72-2.60) 
Slightly/not at all common 26/101 (26%) 1.00 for reference 73/98 (74%) 1.00 for reference 
Perceived bronchiolitis severity     
Extremely/moderately serious 55/190 (29%) 0.38 (0.15-0.93) * 143/188 (76%) 0.63 (0.24-1.65) 
Somewhat serious 19/84 (23%) 0.27 (0.11-0.68) * 62/84 (74%) 0.52 (0.20-1.36) 
Slightly/not at all serious 11/28 (39%) 1.00 for reference 20/26 (77%) 1.00 for reference 
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Table 3: Ordinal regression analysis of factors predicting the willingness of healthcare 
professionals to support RSV vaccination during pregnancy as part of a clinical trial, or if 
routinely recommended 
 
 
*=p<0.05; **=p<0.01; ***=p<0.001 
Variable Number who’d be 
‘very likely’ or 
‘likely’ to support 
RSV vaccination as 
part of a clinical 
trial 
Adjusted odds ratio 
(95% CI) 
Number who’d be 
‘very likely’ or 
‘likely’ to support 
RSV vaccination if 
routinely 
recommended 
Adjusted odds 
ratio (95% CI) 
Professional group  
Obstetrics 34/37 (92%) 2.50 (1.01-6.16) * 33/37 (89%) 4.08 (1.53-9.81) ** 
Midwifery 102/151 (68%) 1.00 for reference 119/151 (79%) 1.00 for reference 
Time in maternity care     
21+ years 46/62 (74%) 0.51 (0.14-1.83) 46/62 (74%) 0.43 (0.12-1.62) 
11-20 years 31/46 (67%) 0.38 (0.11-1.34) 34/46 (74%) 0.79 (0.22-2.86) 
2-10 years 47/66 (71%) 0.68 (0.22-2.10) 60/66 (91%) 1.39 (0.43-4.42) 
<2 years 14/17 (82%) 1.00 for reference 15/17 (88%) 1.00 for reference 
Study site     
Site A 30/41 (73%) 3.94 (1.46-10.61) ** 34/41 (83%) 3.95 (1.39-11.26) * 
Site B 35/53 (66%) 3.19 (1.23-8.30) * 46/53 (87%) 6.23 (2.22-17.46) 
*** 
Site C 51/61 (84%) 5.80 (2.36-14.21) *** 47/61 (77%) 1.97 (0.81-4.83) 
Site D 22/37 (59%) 1.00 for reference 29/37 (78%) 1.00 for reference 
Has own children     
Yes 88/127 (69%) 0.59 (0.28-1.24) 101/127 (80%) 0.86 (0.39-1.91) 
No 50/65 (77%) 1.00 for reference 55/65 (85%) 1.00 for reference 
Ethnicity     
White British 126/175 (72%) 1.01 (0.34-3.06) 142/175 (81%) 1.41 (0.44-4.46) 
Non-White British 12/17 (71%) 1.00 for reference 14/17 (82%) 1.00 for reference 
RSV experience     
Direct experience 22/26 (85%) 2.65 (0.79-8.86) 24/26 (92%) 1.41 (0.39-5.07) 
Indirect experience 20/27 (74%) 1.17 (0.42-3.31) 23/27 (85%) 0.74 (0.25-2.22) 
No experience 96/139 (69%) 1.00 for reference 109/139 (78%) 1.00 for reference 
RSV familiarity     
Good/some understanding 19/22 (86%) 4.42 (1.10-17.83) * 20/22 (91%) 6.07 (1.23-29.93) * 
Poor understanding 87/114 (76%) 1.81 (0.88-3.73) 91/114 (80%) 1.07 (0.51-2.24) 
No understanding  32/55 (58%) 1.00 for reference 44/55 (80%) 1.00 for reference 
Perceived RSV frequency     
Extremely common 29/36 (81%) 1.43 (0.45-4.51) 30/36 (83%) 1.96 (0.57-6.76) 
Moderately/somewhat common 84/116 (72%) 0.92 (0.43-1.98) 95/116 (82%) 1.20 (0.54-2.67) 
Slightly/not at all common 25/39 (64%) 1.00 for reference 30/39 (77%) 1.00 for reference 
Perceived RSV severity     
Extremely serious 27/35 (77%) 4.85 (1.11-21.28) * 26/35 (74%) 1.25 (0.28-5.55) 
Moderately/somewhat serious 113/138 (82%) 4.16 (1.26-13.75) * 117/138 (85%) 4.41 (1.32-14.78) * 
Slightly/not at all serious 8/17 (47%) 1.00 for reference 12/17 (71%) 1.00 for reference 
Bronchiolitis familiarity and 
experience 
    
Good/moderate understanding and 
indirect/direct experience  
58/77 (75%) 0.84 (0.10-6.94) 66/77 (86%) 0.99 (0.12-8.35) 
Slight understanding 78/111 (70%) 0.98 (0.13-7.49) 87/111 (78%) 0.98 (0.13-7.56) 
No understanding 2/4 (50%) 1.00 for reference 3/4 (75%) 1.00 for reference 
Perceived bronchiolitis frequency     
Extremely common 29/34 (85%) 1.05 (0.34-3.25) 27/34 (79%) 0.55 (0.17-1.80) 
Moderately/somewhat common 88/124 (71%) 1.44 (0.63-3.29) 104/124 (84%) 1.07 (0.45-2.51) 
Slightly/not at all common 21/34 (62%) 1.00 for reference 25/34 (74%) 1.00 for reference 
Perceived bronchiolitis severity     
Extremely serious 36/47 (77%) 0.35 (0.054-2.28) 38/47 (81%) 0.96 (0.15-6.39) 
Moderately/somewhat serious 96/136 (71%) 0.29 (0.052-1.65) 111/136 (82%) 0.54 (0.10-2.99) 
Slightly/not at all serious 6/9 (67%) 1.00 for reference 7/9 (78%) 1.00 for reference 
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Supplementary information 
 
 
1) Questions for pregnant women analysed in this study 
 
(1) Before taking part in this survey, how familiar were you with Respiratory Syncytial Virus 
(sometimes shortened to RSV)? 
☐ I have never heard of it 
☐ I have heard of it, but don’t really know what it is 
☐ I know some facts about what it is  
☐ I have a good understanding about RSV infection and its implications  
 
(2) What experience do you have of RSV? 
☐ I have no experience of it 
☐ I know someone who has experience of it 
☐ I have direct experience of it  
 
(3) How common do you think RSV infection is in babies and young children? 
☐ Not at all common 
☐ Slightly common 
☐ Somewhat common 
☐ Moderately common 
☐ Extremely common 
 
(4) How serious do you think RSV infection is for babies and young children? 
☐ Not at all serious 
☐ Slightly serious 
☐ Somewhat serious 
☐ Moderately serious 
☐ Extremely serious 
      
(5) Before taking part in this survey, how familiar were you with bronchiolitis in babies and 
young children? 
☐ I have never heard of it 
☐ I have heard of it but don’t know what it is 
☐ I know some facts about it 
 ☐ I know what it is and know someone who has experience of it 
☐ I know what it is and have direct experience of it  
 
(6) How common do you think bronchiolitis is in babies and young children? 
☐ Not at all common 
☐ Slightly common 
☐ Somewhat common 
☐ Moderately common 
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☐ Extremely common 
 
 
(7) How serious do you think bronchiolitis is for babies and young children? 
☐ Not at all serious 
☐ Slightly serious 
☐ Somewhat serious 
☐ Moderately serious 
☐ Extremely serious 
 
(8) Would you be potentially willing to receive a RSV vaccine during pregnancy as part of a 
research study to determine its safety and effectiveness, before the vaccine is approved for 
routine use?   
 
Your response to this question will not affect whether or not you receive further information about such 
studies and does not mean that you are agreeing to take part in any vaccine research studies.  
 
☐ Extremely unlikely 
☐ Unlikely 
☐ Neutral/not sure 
☐ Likely 
☐ Extremely likely   
 
(9) What information would you consider to be important when considering taking part in a 
research study of a RSV vaccine?  
 
Please rank the top 3 most important to you: (1= most important information for you to know) 
 
☐ How common RSV is 
☐ How serious RSV is 
☐ Number of healthy adults who have received the vaccine 
☐ Number of pregnant women who have received the vaccine 
☐ Likelihood of side effects for me 
☐ Likelihood of side effects for my baby 
 
(10) One type of a research study is a “Randomised Controlled Trial” where there are two (or 
more) groups who are treated exactly the same, except only one group gets the true vaccine 
under investigation. The other group may get a ‘placebo’ (dummy or inactive) injection.  
 
This type of study allows the researchers to check that any differences between the groups are 
due to the vaccine only. Importantly, patients or staff do not get to choose whether they receive 
the proper vaccine or the dummy. 
 
After reading the above information: 
☐ I would be less likely to take part as I would want to guarantee that I would have the vaccine  
☐ I would be more likely to take part as I might not get the vaccine  
☐ This would not affect my decision 
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(11) In some randomised controlled trials, patients are given different doses (amounts) of the 
vaccine under investigation in order to work out which is the best dose to use in future vaccines. 
These different doses would be calculated before the trial starts, but patients or staff involved in 
the study do not get to choose which of these doses they receive. 
After reading the above information: 
☐ I would be less likely to take part  
☐ I would be more likely to take part 
☐ This would not affect my decision 
 
(12) What other factors would discourage you from taking part in a research study of a vaccine 
in pregnancy? 
Please rank the following: (1= factor that would most discourage you, 4= factor least likely to 
discourage you) 
☐ Number of hospital visits 
☐ Number of home visits 
☐ Number of blood tests for me 
☐ Number of blood tests for baby 
☐ Other, please 
specify……………………………………………………………………………………………………
… 
 
(13) How would you most like to be approached about taking part in a research study? 
Tick one answer: 
☐ Asked by my midwife 
☐ Asked by my obstetrician  
☐ Asked by my GP 
☐ Given a leaflet/poster with contact details for the study team 
☐ Adverts of the internet (e.g. pregnancy forums) 
☐ Email from the study team  
☐ Approached directly by the study midwife/doctor 
☐ I wouldn’t mind how I was approached 
☐ 
Other:……………………………………………………………………………………………………
……………………… 
 
(14) If you were approached about taking part in a research study, how much time would you 
like to fully consider whether or not you would like to take part? 
☐ <24 hours 
☐ 1-2 days 
☐ 3-7 days 
☐ 2-3 weeks 
☐ >1 month 
 
(15) Would you be willing to receive this vaccine in pregnancy if it was routinely recommended 
for use in pregnancy in the NHS? 
☐ Definitely 
☐ Probably 
☐ Maybe 
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☐ Probably not 
☐ Definitely not  
 
(16) There are a number of different vaccines that are being designed for use in pregnancy to 
protect mothers and infants against severe infection. How many vaccines would be acceptable to 
you in pregnancy? 
☐ 0 
☐ 1 
☐ 2 
☐ 3 
☐ 4 
☐ 5 
☐ More than 5 
 
(27) How old are you in years? 
16-24 ☐  25-30 ☐ 31-35 ☐ 36-40 ☐ 41-45 ☐  46+ ☐  
  
(28) How many weeks pregnant are you? 
Less than 12 ☐  12-16 ☐ 17-20 ☐ 21-30 ☐ 31-36 ☐ 37+ ☐  
 
(19) To what ethnic group do you feel you belong? (Please circle) 
 
White       Black / African / Caribbean / Black 
British 
- English / Welsh / Scottish / Northern Irish   - African  
/ British Irish       - Caribbean  
- Gypsy or Irish Traveller      - Other (please 
specify)…………………………….. 
- Other (please specify) …………………………….. 
 
Mixed/Multiple ethnic groups    Other ethnic group 
- White and Black Caribbean     - Arab  
- White and Black African      - Other (please 
specify)………………………… 
- White and Asian  
- Other (please specify) …………………………….. 
 
Asian / Asian British     I’d prefer not to say 
- Indian  
- Pakistani  
- Bangladeshi  
- Chinese  
- Other (please specify) ………………………… 
 
(20) Have you had any children before?   
☐ Yes. 
If yes, how many?.................................................................... 
What are their ages? 
Child 1: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐  
Child 2: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐ 
Child 3: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐  
☐ No  
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(21) Optional: Do you have any comments or concerns about any of the issues raised in the 
questionnaire? 
 
 
2) Questions for healthcare professionals analysed in this study 
 
(1) Before taking part in this survey, how familiar were you with Respiratory Syncytial Virus 
(sometimes shortened to RSV)? 
☐ I have never heard of it 
☐ I have heard of it, but don’t really know what it is 
☐ I know some facts about what it is  
☐ I have a good understanding about RSV infection and its implications  
 
(2) What experience do you have of RSV? 
☐ I have no experience of it 
☐ I know someone who has experience of it 
☐ I have direct experience of it  
 
(3) How common do you think RSV infection is in young children? 
☐ Not at all common 
☐ Slightly common 
☐ Somewhat common 
☐ Moderately common 
☐ Extremely common 
      
(4) How serious do you think RSV infection is for young children? 
☐ Not at all serious 
☐ Slightly serious 
☐ Somewhat serious 
☐ Moderately serious 
☐ Extremely serious 
      
(5) Before taking part in this survey, how familiar were you with bronchiolitis in young children? 
☐ I have never heard of it 
☐ I have heard of it but don’t know what it is 
☐ I know some facts about it 
 ☐ I know what it is and know someone who has experience of it 
☐ I know what it is and have direct experience of it  
 
(6) How common do you think bronchiolitis is in young children? 
☐ Not at all common 
☐ Slightly common 
☐ Somewhat common 
☐ Moderately common 
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☐ Extremely common 
 
 (7) How serious do you think bronchiolitis is for young children? 
☐ Not at all serious 
☐ Slightly serious 
☐ Somewhat serious 
☐ Moderately serious 
☐ Extremely serious 
 
(8) Would you be potentially willing to support a randomised controlled trial of RSV vaccine in 
pregnancy to determine its safety and how well it prevents infection in children, by signposting 
the study to women?  
Your response to this question will not affect whether or not you receive further information about such 
studies 
 
☐ Extremely unlikely 
☐ Unlikely 
☐ Neutral/not sure 
☐ Likely 
☐ Extremely likely  
 
(9) Would you be willing to support the administration of this vaccine if it was routinely 
recommended for use in the NHS?  
☐ Definitely 
☐ Probably 
☐ Maybe 
☐ Probably not 
☐ Definitely not 
 
(10) What factors would influence your decision regarding whether or not you would be willing 
to support involvement in a RSV vaccine research study before it is licensed? 
 
Please rank the top 3 factors:  (1= factor that would most influence you) 
 
☐ The number of pregnant women who had previously received the vaccine in research studies 
☐ How common RSV is in children 
☐ Seriousness of RSV infection in young children  
☐ How effective the vaccine is in preventing RSV infection 
☐ How effective the vaccine is in preventing severe RSV disease 
☐ Risk of side effects for the mother 
☐ Risk of side effects for developing baby 
☐ Other (please specify): 
……………………………………………………………………………………………………. 
 
(11) How many pregnant women would the vaccine have to be safely tested on in a research 
study for you to consider supporting such a trial? 
☐ None 
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☐ Over 10 
☐ Over 100 
☐ Over 500 
☐ Over 1000 
☐ Over 5000 
☐ Over 10,000 
☐ I would not support such a trial  
 
(12) Which healthcare professional group do you belong to?       
☐ Obstetrics 
☐ Midwifery 
☐ Other (please state) 
………………………………………………………………………………………… 
 
(13) How long have you worked in maternity care? 
☐ Under 2 years 
☐ 2-5 years 
☐ 6-10 years  
☐ 11-15 years 
☐ 16-20 years  
☐ 21+ years  
 
(14) What is your grade? 
1. Midwifery/nursing staff 
Band 4 ☐       Band 5 ☐       Band 6 ☐         Band 7 ☐        Band 8 ☐        Band 9 ☐ 
2. Obstetricians 
ST 1-3 (or equivalent) ☐     ST 4-6 (or equivalent) ☐      ST 7-8 (or equivalent) ☐     Consultant ☐ 
 
(15) Have you had any children before?   
☐ Yes. 
If yes, how many?.................................................................... 
What are their ages? 
Child 1: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐  
Child 2: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐ 
Child 3: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐  
Child 4: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐    
☐ No  
  
(16) To what ethnic group do you feel you belong? (Please circle) 
 
White       Black / African / Caribbean / Black 
British 
- English / Welsh / Scottish / Northern Irish   - African  
/ British Irish       - Caribbean  
- Gypsy or Irish Traveller      - Other (please 
specify)…………………………….. 
- Other (please specify) …………………………….. 
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Mixed/Multiple ethnic groups    Other ethnic group 
- White and Black Caribbean     - Arab  
- White and Black African      - Other (please 
specify)………………………… 
- White and Asian  
- Other (please specify) …………………………….. 
 
Asian / Asian British     I’d prefer not to say 
- Indian  
- Pakistani  
- Bangladeshi  
- Chinese  
- Other (please specify) ………………………… 
 
(17) Optional: Do you have any comments or concerns about vaccination or vaccine research 
studies during pregnancy? 
 
 
 
 
 
 
 
 
3) Free-text comments from pregnant women and healthcare professionals 
 
Response to the question: Do you have any comments or concerns about vaccination or vaccine 
research studies during pregnancy? 
 
Pregnant women 
 
1. I think vaccine trials are very risky even though very important so every available information 
should be made available to the participant before commencing including all known possible 
side effects 
 
2. Many vaccines contain unsafe levels of mercury in some cases some are produced on human 
tissue (DNA) and contain various other toxins. I believe a baby is born with a perfect immune 
system which takes up to 3 years to fully develop and that it's not healthy injecting a 
perfectly healthy child with chemicals and toxins (mercury) 
 
3. I am glad to hear that the NICE guidelines will be reviewed and that possibly new vaccines 
will be introduced 
 
4. I am taking part in a RSV vaccine trial 
 
5. I'm very keen for my baby to have as many vaccines as possible & fully support such research 
 
6. I would want the vaccine fully tested and approved before I would have it 
 
7. Our daughter suffered from bronchiolitis at age 2 weeks old so as long as the vaccine was 
safe we would definitely have it to prevent this baby suffering like our daughter did 
 
8. I would consider vaccination if I was having a normal singleton pregnancy 
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9. I'm a bit of a unique case because I've had an adverse reaction to a vaccine in the past and 
wouldn't risk it in pregnancy unless I had to 
 
10. Child died at 20 months. RSV sounds very like what my son had when he died 
 
11. No concerns. I am very pro vaccinations both for myself during pregnancy and for my 
children  
 
12. I am having a slightly bumpy pregnancy and this is one of the reasons I would be reluctant to 
take part in a research study which could increase the risks for the pregnancy complications. 
If I was a low-risk person I would be more willing to take part. Likewise, if this wasn't my first 
baby I might be more willing 
 
13. Information about the potential side effects of the trial vaccinations would have been helpful 
for me to make more informed decisions 
 
14. I've not heard of RSV before sounds concerning and something I would have liked to have 
been told about earlier in my pregnancy 
 
15. I've heard of many children developing chest infections as young babies and anything to 
avoid this I feel should be actively encouraged 
 
16. I would like the opportunity to ask more questions and have more information before 
agreeing to vaccination  
 
17. I would only have medication in pregnancy that has been approved by the BMA. Diabetics 
have a lot of complications anyway 
 
18. No - thank you for all the amazing work/research you do 
 
19. I believe the stage of drug trial to be more pertinent to the decision-making process than the 
number of vaccinations received. 
 
20. My concern in taking part in a research study is the unknown side effects to my baby and 
whether the potential side effects would cause more harm than the virus itself. Whilst I 
appreciate research needs to be done and the vaccine will have been thoroughly tested on 
other test groups testing pregnant women/babies is still a concern for me  
 
21. Not really aware enough of the issue to comment on some of the questions 
 
22. In my experience, the flu vaccine has made me ill. I would not feel comfortable having a trial 
vaccine as a first-time mother 
 
Maternity healthcare professionals 
 
1. I would want to see safety data in non-pregnant participants concerning side effects and 
efficacy before I supported vaccine studies on pregnant women. I understand that 
effectiveness in preventing baby bronchiolitis could not be assessed using non-pregnant 
subjects but would reassure health workers that we aren't supporting an action that could 
cause harm. 
 
2. I would worry about safety /side effects to mum and baby if not tested before being given to 
pregnant women 
 
3. Knowledge to midwives about RSV is very limited without having first-hand experience of it 
or working alongside paediatric teams. It’s not widely taught in training perhaps because our 
care for infants doesn't go much beyond 10-28 days postnatally  
 
 36 
4. My son needed ECMO because of this infection but he was too unstable to transfer to Gt O S 
we very nearly lost him at 12 days old. He caught it from his sister who was 2 and poorly 
when he was born. This serious infection wiped the first 2 months of a normal newborn 
period for us. He did get asthma as a child and took months to catch up.  
 
5. Side effects - baby especially. 
 
6. I'm not convinced that RS virus needs vaccination. Depends on the severity of chance of later 
disease in the child. I think we build up immunity ourselves and therefore the number 
needed to treat is probably high to prevent severe RS virus infection in children. 
 
7. I would want some evidence that the vaccine is safe. 
 
8. My children were born at 27/40 and 32/40 week’s gestation. For our 27/40 week-old baby it 
was very serious. 
 
9. Potential risks to unborn and ability to be honest with mother about risks v benefits. 
 
10. Risk to unborn. 
 
11. Can’t really answer question of how many women vaccines would have to be safely tested 
on as I don't know what the predicted rate of adverse reactions/side effects. As long as 
sufficiently powered I would be happy. No concerns as long as properly conducted. 
Vaccination research environment is heavily regulated so very confident. 
 
12. That the vaccine is safe for the mother and unborn child. This has to be paramount and is of 
high concern with the majority of the public. 
 
13. When testing for side effects -there should be follow-up of at least 5 years on the child 
whose mother received the vaccine. We are woefully short on long-term effects and in order 
to fully discuss (and understand) the effects of vaccinations in pregnancy these time-frames 
should be mandatory. Lack of long-term data does not reassure me that we should be 
vaccinating in pregnancy. 
 
14. Effect on the baby that are so far unknown. Another vaccine could it be combined with 
present vaccines? 
 
15. I would worry about a trial re the long term unknown effects on the health of children whose 
mothers received the vaccine whilst they were in utero. 
 
16. Yes, the potential risks to mother and unborn baby 
 
